Clinical Trials
127 trialsLifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma
University of Kansas Medical Center
SBRT/IL-2
Providence Health & Services
Therapy for Children With Advanced Stage Neuroblastoma
St. Jude Children's Research Hospital
Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer
H. Lee Moffitt Cancer Center and Research Institute
IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients
H. Lee Moffitt Cancer Center and Research Institute
Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma
M.D. Anderson Cancer Center
Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma
H. Lee Moffitt Cancer Center and Research Institute
TIL Therapy in cSCC and MCC
Dana-Farber Cancer Institute
Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI...
National Institutes of Health Clinical Center (CC)
Gene and Vaccine Therapy in Treating Patients With Advanced Malignancies
Jonsson Comprehensive Cancer Center
Assessment of Efficacy and Safety of PD-1 Monoclonal Antibody Combined With IL-2 and CapeOX in Neoadjuvant Therapy for Locally Advanced Rectal Cancer Prior to Surgery: A Prospective, Multi-center, Randomized Controlled Study
The First Affiliated Hospital with Nanjing Medical University
LuminICE-203
Affimed GmbH
DiTuSarc
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Safety and Efficacy Study of Immunotherapy With Rituximab and Interleukin-2 in Patients With Non-Hodgkin's Lymphoma
Thomas Jefferson University
Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma
M.D. Anderson Cancer Center
Study of High Dose Interleukin-2 (IL-2) and Stereotactic Body Radiation (SBRT) in Patients With Metastatic Renal Cancer
Providence Health & Services
High Dose IL-2 in Combination With Anti-PD-1 to Overcome Anti-PD-1 Resistance in Metastatic Melanoma and Renal Cell Carcinoma
University of California, San Diego
PragmaTIL
Vall d'Hebron Institute of Oncology
Study of Adoptive Transfer of iNKT Cells Combined With TAE/TACE to Treat Unresectable HCC
Beijing YouAn Hospital
Anti-PD-1 Antibody With HD IL-2 in Metastatic Melanoma
Hoosier Cancer Research Network
COREVAX-1
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
RaC-Ad
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Safety Study of Dinutuximab Combined With Immunotherapy to Treat Neuroblastoma
Fundació Sant Joan de Déu
Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma
National Cancer Institute (NCI)
Vaccine Therapy in Treating Patients With Metastatic Melanoma of the Eye
National Cancer Institute (NCI)
Radiation and Combination Immunotherapy for Melanoma
Masonic Cancer Center, University of Minnesota
PANCEP-1
Sahlgrenska University Hospital
A Clinical Study of Recombinant Human Vascular Endothelial Inhibitor in Combination With PRaG for Advanced Refractory Non-small Cell Lung Cancer
Second Affiliated Hospital of Soochow University
High Dose IL 2 and Entinostat in RCC
Hoosier Cancer Research Network
Universal Granulocyte Macrophage-colony Stimulating Factor (GM-CSF)-Producing and GM.CD40L for Autologous Tumor Vaccine in Mantle Cell Lymphoma
H. Lee Moffitt Cancer Center and Research Institute
High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery
Rutgers, The State University of New Jersey
METILDA
The Christie NHS Foundation Trust
Cytokine-induced Memory-like NK Cells in Combination With Chemotherapy in Pediatric Patents With Refractory or Relapsed AML
Washington University School of Medicine
Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma Patients
Sheba Medical Center
Vinorelbine Metronomic Chemotherapy Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of Advanced Refractory Non-small Cell Lung Cancer and Breast Cancer(PRaG 6.0)
Second Affiliated Hospital of Soochow University
Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma
St. Jude Children's Research Hospital
PRaG Regimens Rechallenge for Patients With Resistance to PD1/PD-L1 Inhibitors in Refractory Advanced Solid Tumors.
Second Affiliated Hospital of Soochow University
Hypofractionated Radiotherapy Combined With PD-1 Inhibitor Sequential GM-CSF and IL-2 for the Treatment of Advanced Refractory Solid Tumors (PRaG2.0)
Second Affiliated Hospital of Soochow University
Cytokine-induced Memory-like NK Cells in Relapsed/Refractory AML and MDS
Washington University School of Medicine
ADC Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of HER-2 Positive Advanced Solid Tumors(PRaG3.0)
Second Affiliated Hospital of Soochow University
High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy for Metastatic Renal Cancer
University of Texas Southwestern Medical Center
A Study of TroVax Vaccine Given in Conjunction With IL-2 for Treatment of Stage IV Renal Cell Cancer
Oxford BioMedica
Safety and Biological Activity of TroVax® Vaccine Given With IL-2 in Renal Cell Carcinoma
Oxford BioMedica
NK Cells as Consolidation Therapy of Acute Myeloid Leukemia in Children/Adolescents
Instituto de Investigación Hospital Universitario La Paz
Biochemotherapy With Temozolomide for Metastatic Melanoma
M.D. Anderson Cancer Center
Haploidentical Natural Killer (NK) Cells in Patients With Relapsed or Refractory Neuroblastoma
M.D. Anderson Cancer Center
NK Cell Based Non-Myeloablative Transplantation in Acute Myeloid Diseases
Masonic Cancer Center, University of Minnesota
Trial of Outpatient Intravenous Interleukin-2 in Malignant Melanoma and Metastatic Kidney Cancer
Loma Linda University
High-Dose Interleukin-2 (HDIL-2), Combined With recMAGE-A3 + AS15 ASCI
M.D. Anderson Cancer Center
Modified Tumor Infiltrating Lymphocytes for Metastatic Melanoma
National Institutes of Health Clinical Center (CC)